|
Delirium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Seven (31.8%) Parkinson's disease patients developed neuropsychiatric complications (psychosis and delirium) after STN-DBS implantation surgery with full recovery in short follow up.
|
30267364 |
2020 |
|
Dysarthria
|
0.010 |
Biomarker
|
disease |
BEFREE |
Post hoc analysis indicated that patients with dysarthria and a shorter duration of DBS may be improved by short PW stimulation.
|
31571270 |
2020 |
|
Autistic Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings are thought to be useful for understanding pathological conditions related to DBS such as cancer and non-syndromic autism in future.
|
31089935 |
2019 |
|
Blepharospasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, DBS for PD can cause dystonia such as blepharospasm and bilateral pallidal DBS for dystonia can result in features of parkinsonism.
|
31078682 |
2019 |
|
Cluster Headache
|
0.010 |
Biomarker
|
disease |
BEFREE |
We confirm the efficacy of VTA-DBS in the treatment of medically refractory chronic cluster headache.
|
30897944 |
2019 |
|
Down Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for confounders (age, level of ID, history of falls, comorbidities and number of non-DBI medications, Down syndrome (grip strength only) and gender (timed up and go and Barthel Index)), neither grip strength nor timed up and go were significantly associated with DBI, DBA or DBS score > 0 (p > 0.05).
|
31234775 |
2019 |
|
Drug habituation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We also propose possible pathophysiological explanations for the phenomenon and define a nomenclature of the associated features: early versus late DBS failure; tremor rebound versus habituation (to be preferred over tolerance).
|
31433906 |
2019 |
|
Influenza
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tamiflu® (oseltamivir phosphate, OST) is an antiviral drug used for the pandemic treatment of avian influenza but few data are available regarding its toxicity.
|
30669952 |
2019 |
|
Onchocerciasis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Analysis revealed that serum concentrations (calculated from DBS) within the respective reference ranges were attained in only 52.9% of the 68 Nodding syndrome patients treated with valproic acid, in 21.4% of the 56 Ugandan epilepsy patients treated with carbamazepine, and in 65.7% of the 137 onchocerciasis-associated epilepsy patients from the DRC treated with phenobarbital.
|
31834012 |
2019 |
|
Stuttering
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Although pallidal deep brain stimulation (GPi-DBS) is an effective treatment for dystonia, it may cause important stimulation-induced side-effects such as hypokinetic dysarthria or stuttering.
|
29576500 |
2019 |
|
Unipolar Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long-term outcome data were collected for 28 patients (20 with major depressive disorder and seven with bipolar II disorder; one patient in the major depression subgroup was later reclassified as having bipolar II disorder) receiving SCC DBS for 4-8 years.
|
31581800 |
2019 |
|
Choreoathetosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We aimed to assess whether the thalamic ventral intermediate nucleus (Vim) might be an alternative DBS target in dystonia-choreoathetosis.
|
30718219 |
2019 |
|
Hemiballismus
|
0.010 |
Biomarker
|
disease |
BEFREE |
More studies are required to establish which DBS target requires the least amount of stimulation to treat hemiballism.
|
31541757 |
2019 |
|
Bipolar II disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long-term outcome data were collected for 28 patients (20 with major depressive disorder and seven with bipolar II disorder; one patient in the major depression subgroup was later reclassified as having bipolar II disorder) receiving SCC DBS for 4-8 years.
|
31581800 |
2019 |
|
Absence of sensation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here, we present the comparative research of neuronal activity in subthalamic nucleus (STN) of 8 Parkinsonian patients undergoing DBS surgery in awake state and under propofol anaesthesia using different statistical approaches.
|
30121284 |
2019 |
|
Hypothalamic hamartomas
|
0.010 |
Biomarker
|
disease |
BEFREE |
ABBREVIATIONS AED = antiepileptic drug; ANT = anterior nucleus of the thalamus; BOLD = blood oxygen level dependent; CCEP = cortico-cortical evoked potential; DBS = deep brain stimulation; ECoG = electrocorticography; ERSET = Early Randomized Surgical Epilepsy Trial; FCD = focal cortical dysplasia; HH = hypothalamic hamartoma; LITT = laser interstitial thermal therapy; RCT = randomized controlled trial; r-fMRI = resting-state functional MRI; RNS = responsive neurostimulation; SEEG = stereo-electroencephalography; VNS = vagus nerve stimulation.
|
30970205 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, the level of serum HOTAIR was positively associated with the levels of serum bone metabolic markers (CTx, OST, B-ALP and PINP) and may serve as a reasonable biomarker for PCa bone metastasis.
|
31028291 |
2019 |
|
Extrapyramidal dysarthria
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To objectively investigate the impact of GPi-DBS on patients with dystonia on speech fluency, intelligibility, and key aspects of hyperkinetic and hypokinetic dysarthria.
|
29576500 |
2019 |
|
Parkinsonian tremor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The subthalamic nucleus (STN), the internal globus pallidus (GPi), ventral intermediate nucleus (Vim), and pedunculopontine nucleus (PPN) are reportedly effective DBS targets for control of Parkinsonian tremors.
|
30853908 |
2019 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, the level of serum HOTAIR was positively associated with the levels of serum bone metabolic markers (CTx, OST, B-ALP and PINP) and may serve as a reasonable biomarker for PCa bone metastasis.
|
31028291 |
2019 |
|
Major Depressive Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long-term outcome data were collected for 28 patients (20 with major depressive disorder and seven with bipolar II disorder; one patient in the major depression subgroup was later reclassified as having bipolar II disorder) receiving SCC DBS for 4-8 years.
|
31581800 |
2019 |
|
Positive myoclonus
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The objective of this study was to assess the long-term clinical outcome, quality of life, and social adjustment of GPi-DBS in patients with ε-sarcoglycan (DYT11)-positive myoclonus-dystonia.
|
30302819 |
2019 |
|
Myoclonic dystonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to assess the long-term clinical outcome, quality of life, and social adjustment of GPi-DBS in patients with ε-sarcoglycan (DYT11)-positive myoclonus-dystonia.
|
30302819 |
2019 |
|
Grand mal status epilepticus, refractory
|
0.010 |
Biomarker
|
disease |
BEFREE |
This case demonstrates the effectiveness of ANT-DBS for emergency super-refractory convulsive SE with both positive and negative outcomes.
|
31403465 |
2019 |
|
End stage Parkinson's disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
DBS generator replacement surgery is low risk, even in patients who have end-stage PD.
|
31059853 |
2019 |